BioCentury | Feb 4, 2021
Product Development

Preclinical antiviral strategies for COVID-19: Data Byte

...3C-like protease inhibitor PF-07304814 in Phase I testing. Spurred by a desire not to get caught flat-footed...
BioCentury | Dec 24, 2020
Politics, Policy & Law

Judge blocks Trump administration’s most favored nation drug price controls

...good cause exception in this case falls flat,”...
BioCentury | Dec 19, 2020
Regulation

U.K. selects first drugs for pathfinding antimicrobial resistance initiative

...market for antibiotics, will pay manufacturers a flat...
BioCentury | Dec 15, 2020
Deals

In $39B deal, AZ looks to grow rare disease business while Alexion’s investors gain value recognition

...about $47 billion, and has remained relatively flat...
BioCentury | Dec 4, 2020
Politics, Policy & Law

Trade groups move to derail rule that would tie drug prices with those in other countries

...for Economic Cooperation and Development, plus a flat...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...for Economic Cooperation and Development, plus a flat...
BioCentury | Oct 21, 2020
Product Development

Aducanumab looms larger after Biogen cuts guidance, shelves programs in MS and SMA

...Spinraza, came in at $495 million, short of analysts’ $511 million consensus. Spinraza sales were flat...
BioCentury | Oct 2, 2020
Finance

3Q20 Wrap: Biotech’s sideways quarter

...Biotech midcaps the single bright spot amongst mostly flat valuations in 3Q20 By stephen hansen, associate...
...stephen hansen, associate editor The third quarter saw most tiers of the biotech sector trade flat...
...expiration of the lock-up period for IPO investors.The $1-$4.9 billion market cap group were largely flat...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

...have played this.” While biotech indexes were largely flat...
BioCentury | Oct 1, 2020
Product Development

‘Flipting’ the switch: a technological prescription for lower drug costs. Guest Commentary

...Flipt, a startup that charges a transparent flat...
...with a plan where sponsors pay a flat...
Items per page:
1 - 10 of 691